Oral Glucose Tolerance test (75g 2-hour): Standard oral glucose tolerance test with blood draws every 15-30 minutes for a 2-hour span
Study summary
Goals: The long-term use of hormonal birth control has been shown to effect glucose handling, or blood sugar regulation, and potentially lead to insulin resistance which increases a person's risk for metabolic diseases such as type 2 diabetes. The goal of this study is to investigate how the body handles glucose, in three groups of young, healthy females: NAT (naturally cycling, or not using hormonal birth control), OCP (taking a birth control pill), and IUD (using an intrauterine device). Objectives: We will investigate if the body's ability to handle glucose differs between these groups. We will also explore if these differences are linked to the levels of primary sex hormones in females, estrogen and progesterone, and if the synthetic versions produced by hormonal birth control have the same negative effect. We will use an oral glucose tolerance test to investigate these potential differences, having participants drink a 75 gram glucose beverage and taking blood samples every 15-30 minutes for a 2-hour timespan. These blood samples will be used to measure glucose and insulin levels in the blood to determine any changes that occur in the body in response to glucose.
Eligibility
Sex
FEMALE
Min age
18 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Within 18-45 years
* BMI between 18.5 and 30.0 kg/m2
* Weight stable for the past 6 months (± 2kg)
* VO2peak values within a below average to above average rangea
* Fasting blood glucose \<6.0 mMb
* Resting blood pressure \<140/90 mmHg
NAT females:
• Regular menstrual cycle for \> 6 months (defined as a cycle length of 21-35 days)
OCP users:
* Use of combined OCPs as prescribed for \> 3 months
* Second generation levonorgestrel drugs only
* Monophasic formulations only (Alesse, Alysena, Audrina, Aviane, Min-Ovral, Ovima, or Portia)
IUD users:
* Insertion of IUD no fewer than 3 months prior to beginning of study
* Hormonal, levonorgestrel-releasing IUD (Kyleena or Mirena)
Exclusion Criteria:
* Smoking
* Diabetes, cancer, or other metabolic disorders
* Cardiac or gastrointestinal problems
* Infectious disease
* Barium swallow or nuclear medicine scan in the previous 3 weeks
* Pregnant or breastfeeding
* Diagnosis of polycystic ovary syndrome
* Endometriosis
* Use of emergency contraception (e.g., Plan B) within the previous 3 months
NAT females:
• Use of any type of hormonal contraceptive in the previous 3 months
OCP users:
* Not using OCP as prescribed (e.g. missing doses or taking drug inconsistently)
* Use of OCP for longer than 3 years.
IUD users:
* Insertion of Kyleena IUD longer than 2 years.
* Insertion of Mirena IUD longer than 4 years.
Primary outcome measure(s)
Glucose tolerance — 2 hours A 2-hour oral glucose tolerance test will be performed in fasted individuals
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
